The global market for Sentinel Node Biopsy was estimated at US$829.3 Million in 2024 and is projected to reach US$1.3 Billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Sentinel Node Biopsy market.
Segments: Product (Surgical Instruments, Imaging Agents, Diagnostic Kits); Procedure (Open Surgery, Minimally Invasive Surgery); Application (Breast Cancer, Colon Cancer, Esophageal Cancer, Others); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Diagnostic Centers)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Sentinel Node Biopsy Market - Key Trends & Drivers Summarized
Why Is Sentinel Node Biopsy Becoming A Crucial Procedure In Cancer Diagnostics?
Sentinel node biopsy (SNB) is a minimally invasive surgical procedure used to determine the spread of cancer, particularly in cases of breast cancer and melanoma. By identifying and analyzing the first lymph node (sentinel node) that cancer cells are likely to reach, SNB helps physicians assess metastasis without requiring a full lymph node dissection. This technique is gaining popularity due to its ability to reduce complications such as lymphedema while maintaining high diagnostic accuracy. With cancer rates rising globally and early detection playing a critical role in improving survival rates, the demand for sentinel node biopsy procedures is growing across healthcare institutions. Additionally, advancements in imaging and molecular diagnostics are further improving SNB precision and reliability.What Technological Innovations Are Enhancing Sentinel Node Biopsy Procedures?
Recent advancements in radiotracer technology, fluorescence-guided surgery, and molecular imaging are revolutionizing sentinel node biopsy. The use of hybrid tracers combining radioactive and fluorescent dyes is improving detection rates, allowing surgeons to precisely locate sentinel lymph nodes. AI-assisted pathology analysis is further enhancing the accuracy of biopsy results, leading to better cancer staging and treatment planning. Additionally, robotic-assisted sentinel node biopsies are being explored to improve precision and minimize patient trauma. These technological breakthroughs are making SNB more efficient, accurate, and widely accessible in oncology practices.Which Medical Sectors Are Driving The Growth Of Sentinel Node Biopsy?
Breast cancer diagnosis remains the leading application of sentinel node biopsy, with SNB becoming the standard of care for early-stage breast cancer patients. Dermatology and oncology practices are also utilizing SNB for melanoma staging, as it allows for precise assessment of lymph node involvement. Emerging applications in head and neck cancer, gynecologic cancers, and prostate cancer are further expanding the use of SNB. Additionally, healthcare providers in emerging markets are adopting SNB as part of improved cancer care strategies, supported by growing investments in oncology infrastructure.What Factors Are Fueling The Growth Of The Sentinel Node Biopsy Market?
The growth of the sentinel node biopsy market is being driven by increasing cancer prevalence, rising adoption of minimally invasive diagnostic procedures, and advancements in imaging technology. Government initiatives promoting early cancer detection and improved access to oncology diagnostics are further supporting market expansion. Additionally, the integration of AI and machine learning in pathology is enhancing SNB accuracy, driving demand among oncologists and surgeons. As precision medicine continues to evolve, SNB will play an increasingly crucial role in personalized cancer treatment and prognosis.Report Scope
The report analyzes the Sentinel Node Biopsy market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Product (Surgical Instruments, Imaging Agents, Diagnostic Kits); Procedure (Open Surgery, Minimally Invasive Surgery); Application (Breast Cancer, Colon Cancer, Esophageal Cancer, Others); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Diagnostic Centers)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Surgical Instruments segment, which is expected to reach US$732.2 Million by 2030 with a CAGR of a 7.9%. The Imaging Agents segment is also set to grow at 6.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $218.0 Million in 2024, and China, forecasted to grow at an impressive 6.9% CAGR to reach $200.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Sentinel Node Biopsy Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Sentinel Node Biopsy Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Sentinel Node Biopsy Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as BD (Becton, Dickinson and Company), Boston Scientific Corporation, C.R. Bard, Inc., Cardinal Health, Care Wise and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 39 Featured):
- BD (Becton, Dickinson and Company)
- Boston Scientific Corporation
- C.R. Bard, Inc.
- Cardinal Health
- Care Wise
- Devicor Medical Products, Inc.
- Devicor Medical Products, Inc.
- Endomagnetics Ltd (Endomag)
- Gamma Medical Technology
- Gamma Probe Technologies
- GE Healthcare
- Hologic, Inc.
- Hologic, Inc.
- Intramedical Imaging LLC
- IsoRay Medical
- KUB Technologies Inc.
- KUB Technologies Inc.
- LabLogic Systems Ltd (Care Wise)
- LabLogic Systems Ltd (Care Wise)
- LymphaTech
- Medtronic
- Navidea Biopharmaceuticals, Inc.
- Philips Healthcare
- Senti Biosciences
- Siemens Healthineers
- Stryker Corporation
- Stryker Corporation
- SurgicEye GmbH
- SurgicEye GmbH
- Varay Laborix
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BD (Becton, Dickinson and Company)
- Boston Scientific Corporation
- C.R. Bard, Inc.
- Cardinal Health
- Care Wise
- Devicor Medical Products, Inc.
- Devicor Medical Products, Inc.
- Endomagnetics Ltd (Endomag)
- Gamma Medical Technology
- Gamma Probe Technologies
- GE Healthcare
- Hologic, Inc.
- Hologic, Inc.
- Intramedical Imaging LLC
- IsoRay Medical
- KUB Technologies Inc.
- KUB Technologies Inc.
- LabLogic Systems Ltd (Care Wise)
- LabLogic Systems Ltd (Care Wise)
- LymphaTech
- Medtronic
- Navidea Biopharmaceuticals, Inc.
- Philips Healthcare
- Senti Biosciences
- Siemens Healthineers
- Stryker Corporation
- Stryker Corporation
- SurgicEye GmbH
- SurgicEye GmbH
- Varay Laborix
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 69 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 829.3 Million |
| Forecasted Market Value ( USD | $ 1300 Million |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
